Moderna Stock News

Moderna's mRNA-1083 vaccine, targeting COVID-19 and flu, in Phase 3, reflects innovation in combination vaccinations. Despite recent financial losses, Moderna maintains strong liquidity with $12.8 bil

The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NA

'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.

Moderna (MRNA) closed the most recent trading day at $108.66, moving +0.07% from the previous trading session.

Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Oppenheimer & Co Analyst, Hartaj Singh, recently upgraded Moderna (MRNA) shares to "Outperform," with a price target of $142 per share. News of the upgrade has caused shares of the stock to trade over

Quint Tatro, Joule Financial president, joins 'Power Lunch' to discuss three stocks, including Apple, Tesla and Moderna.

Moderna Inc. (MRNA) shares soared 15% Tuesday as the vaccine maker got two pieces of positive news.

The biotech sector has been hit hard in recent years. Among the most disappointing stocks for growth investors in this space has certainly been Moderna (NASDAQ: MRNA ), an RNA-based vaccine maker that

The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.

Moderna Inc shares shot up 14% to $113.72 in midday trading on Tuesday after the vaccine maker's CEO confirmed the company's goal of achieving sales growth in 2025.  Brokerage firm Oppenheimer also

U.S. equities began the first day of trading in 2024 mixed at midday, amid concerns over tech exports to China and naval military action in the Middle East. The Dow rose slightly, while the S&P 500 an

Moderna shares rose more than 11% on Tuesday after the vaccine maker's CEO Stéphane Bancel said in a shareholder letter that the company expects its sales to grow in 2025.